Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Julphar
Chubb
Express Scripts
Fuji
Queensland Health
Federal Trade Commission
Deloitte

Generated: November 13, 2018

DrugPatentWatch Database Preview

Imciromab pentetate - Biologic Drug Details

« Back to Dashboard

Summary for imciromab pentetate
Tradenames:1
Patents:3
Applicants:1
BLAs:1

US Patents for imciromab pentetate

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Centocor Inc MYOSCINT imciromab pentetate VIAL 103634 001 1996-07-03 ➤ Try a Free Trial AbbVie, Inc. (North Chicago, IL) ➤ Try a Free Trial DISCN search
Centocor Inc MYOSCINT imciromab pentetate VIAL 103634 001 1996-07-03 ➤ Try a Free Trial AbbVie Inc. (North Chicago, IL) ➤ Try a Free Trial DISCN search
Centocor Inc MYOSCINT imciromab pentetate VIAL 103634 001 1996-07-03 ➤ Try a Free Trial Halozyme, Inc. (San Diego, CA) ➤ Try a Free Trial DISCN search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for imciromab pentetate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000061 Germany ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016000049 Germany ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
2015031 Lithuania ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Medtronic
Daiichi Sankyo
McKinsey
Johnson and Johnson
Fish and Richardson
Chubb
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.